Spira, A. I., Sommerhalder, D., Winterhall, A., Buchholz, T. J., Bateman, T., Kugler, D. G., Rock, D., Alese, O. B., Berz, D., Fakih, M., Hecht, J. R., Oh, D. Y., Sharma, M. R., Wu, C., Nagorsen, D. (2026). A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/microsatellite instability–low (MSI-L) colorectal cancer (CRC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps3678